Andrew D. Smith

Quest Diagnostics, a business founded 46 years ago in a medical resident's two-room apartment, has parlayed the exponential subsequent growth in medical testing into an operation worth $8.5 billion.

New analyses of the BOLERO-2 trial found that everolimus and exemestane produced significantly longer progression-free survival than placebo and exemestane in several previously unstudied patient subgroups.

Infinity Pharmaceuticals of Cambridge, Massachusetts, began its efforts to produce innovative cancer treatments 12 years ago.

Choosing what tests to order for each patient's cancer and then collecting individual samples for those tests has become complex and time consuming-which is why Foundation Medicine expects a big market for FoundationOne.

The translation of scientific advances in nanotechnology into cancer therapies, in vitro assays, and imaging tools is poised for takeoff, amid fresh excitement among investors and a mushrooming of findings from leading research institutions.

New discoveries about tumor biology suggest to many researchers that targeted therapies, when used in appropriate early-stage patients, might significantly boost cure rates and extend lives.

As the cost of sequencing and analyzing genetic data continues to fall, the nation's leading cancer centers keep unveiling ambitious new clinical programs and research projects that will change the way every cancer specialist practices.

Pharmaceutical companies are investing billions of dollars and have more than 900 cancer medications in the pipelines.

Mustard derivatives' potent lethality has ensured its descendents a place in oncology treatment regimens today, even amid advances in targeted therapies.

Biological markers that help clinicians choose which treatment options to pursue for particular patients are attracting increased research interest.

The field of immunotherapy is brimming with questions that researchers are working to answer, and many of those efforts were on display at the ASCO annual meeting.

During the past 20 years, disease management systems have mushroomed in medicine

The technology that enables astronomers to detect eversmaller objects across evergreater distances through ever-heavier interference has found a ready audience among researchers dreaming of adapting it for cancer detection